A retrospective, real world study analysing treatment persistence and adherence to Diroximel Fumarate in Multiple Sclerosis patients
Latest Information Update: 02 Jun 2022
At a glance
- Drugs Diroximel-fumarate (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions; Therapeutic Use
- 26 Apr 2022 Results assessing persistence and adherence in patients with multiple sclerosis (MS) treated with diroximel fumarate (DRF) in real-world clinical practice, presented at the 74th Annual Meeting of the American Academy of Neurology 2022.
- 15 Oct 2021 Results assessing persistence and adherence with diroximel fumarate in real-world clinical practice, presented at the 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis.
- 22 Apr 2021 Results presented at the 73rd Annual Meeting of the American Academy of Neurology